New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:11 EDTRGDX, GSKResponse Genetics receives third GSK milestone payment
Response Genetics (RGDX) announced that it has achieved its third milestone payment from GlaxoSmithKline (GSK) related to the issuance of a U.S. patent for detection of BRAF Mutations.In support of the development of Tafinlar, in March 2010, GSK entered into a non-exclusive license agreement with Response Genetics whereby Response Genetics granted GSK a non-exclusive, sublicenseable license to its proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. The agreement entitled Response Genetics to certain milestone payments. Response Genetics earned its first milestone payment of $500,000 in July of 2012 for submission of the first Premarket Approval and its second milestone payment of $500,000 in May 2013 for the FDA's approval of the PMA. Response Genetics has now earned its third milestone payment of $500,000 upon notice that its patent entitled "Methods, Primers, Probes and Kits Useful for the Detection of BRAF Mutations" was allowed by the United States Patent and Trademark Office.
News For RGDX;GSK From The Last 14 Days
Check below for free stories on RGDX;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
15:35 EDTGSKGlaxoSmithKline receives FDA approval for Arnuity Ellipta in the U.S.
Subscribe for More Information
11:44 EDTGSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
08:30 EDTGSKPernix closes acquisition of Treximet
Subscribe for More Information
08:29 EDTGSKPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:04 EDTGSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
August 18, 2014
13:19 EDTRGDXResponse Genetics to serve as molecular screening center for ALCHEMIST
Response Genetics (RGDX) announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network of the National Cancer Institute, or NCI, a screening trial and two associated treatment trials. The research subcontract was awarded by Leidos Biomedical Research (LDOS).
August 15, 2014
06:34 EDTGSKLawyer says GSK connected investigators to not appeal ruling, Reuters says
Defense lawyer Zhai Jian said GlaxoSmithKline connected corporate investigator Peter Humphrey and his American wife are not aiming to appeal a Chinese court's prison sentence ruling, according to Reuters, citing comments from Jian. Reference Link
August 14, 2014
07:16 EDTRGDXResponse Genetics expects FY14 to be 'transformational year'
The company said, "We expect FY14 could be a transformational year for our company in many respects, not the least of which is we expect both ResponseDX unit volumes and revenue to continue to increase as a result of the initiatives and infrastructure that we implemented over the last two years, including our TC/PC program, our recently acquired and launched ResponseDX: Tissue of OriginTM test, the introduction of several new tests and our where-with-all to provide unique testing services resulting from our patient-centric, multiple technology approach for providing pathologists and oncologists with testing options that they deem best suited for each of their patients based on individual patient needs. With these offerings in place, and our emphasis on execution, we believe we have strengthened our position as a content driven, solid tumor, molecular diagnostics company with a differentiated approach for today's rapidly changing and increasing cost conscious healthcare environment."
07:09 EDTRGDXResponse Genetics reports Q2 EPS (8c) vs. (4c) last year
Subscribe for More Information
August 13, 2014
16:19 EDTGSKOn The Fly: Closing Wrap
Subscribe for More Information
13:13 EDTGSKInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
August 12, 2014
07:15 EDTGSKWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:18 EDTGSKGSK CEO faces pressure as company deals with weak sales, allegations, WSJ says
Subscribe for More Information
August 11, 2014
12:57 EDTGSKGlaxoSmithKline facing new bribery allegations in Syria, Reuters reports
Subscribe for More Information
08:47 EDTGSKGlaxo to conduct Ebola vaccine trials later this year, Guardian says
Subscribe for More Information
August 8, 2014
09:03 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
06:18 EDTGSKRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use